Blood Pressure Goal for Hypertension Management
For most adults with hypertension, target a systolic blood pressure of 120-129 mmHg and diastolic blood pressure <80 mmHg, provided treatment is well tolerated.
Primary Target for Most Adults
The 2024 ESC guidelines provide the most recent and comprehensive recommendation: systolic BP should be targeted to 120-129 mmHg in most adults 1. This represents a Class I recommendation based on contemporary trials including SPRINT, STEP, and ESPRIT. The 2025 AHA/ACC guidelines similarly recommend an SBP goal of at least <130 mmHg, with encouragement to achieve SBP <120 mmHg in adults at increased cardiovascular risk 2, 3.
The diastolic target is <80 mmHg for all hypertensive patients, independent of risk level and comorbidities 1. If diastolic BP remains ≥80 mmHg despite achieving systolic targets of 120-129 mmHg, intensifying treatment to achieve DBP of 70-79 mmHg may be considered 1.
Stepwise Approach to BP Targets
Initial Target
- First objective: Lower BP to <140/90 mmHg in all patients 1
- This should be achieved promptly, ideally within 3 months of initiating therapy
Optimal Target (if tolerated)
- Systolic: 120-129 mmHg (with 120 mmHg being the optimal point in this range) 4, 1
- Diastolic: 70-79 mmHg 1
Modified Targets for Specific Populations
Older Adults (≥65 years)
Target systolic BP to 130-139 mmHg 1. The 2025 AHA/ACC guidelines recommend SBP <130 mmHg for noninstitutionalized, ambulatory, community-dwelling older adults if tolerated 2, 3.
Very Elderly (≥85 years) or Symptomatic Orthostatic Hypotension
Consider more lenient targets (e.g., <140 mmHg) 4, 1. This is a Class IIa recommendation recognizing that intensive targets may not generalize to this population.
Moderate-to-Severe Frailty or Limited Life Expectancy (<3 years)
More lenient targets (e.g., <140/90 mmHg) may be considered 1. This is a Class IIb recommendation, emphasizing individualized care based on clinical judgment and shared decision-making.
High Cardiovascular Risk Patients
The 2025 AHA/ACC defines increased risk as 10-year predicted CVD risk ≥7.5% using PREVENT equations. For these patients, SBP goal of at least <130 mmHg with encouragement to achieve <120 mmHg is a Class I recommendation 2, 3.
Key Evidence Supporting Lower Targets
The recommendation for 120-129 mmHg is based on meta-analyses showing that in adults at high CVD risk, targeting SBP <130 mmHg resulted in significant reductions in cardiovascular disease, stroke, coronary heart disease, heart failure, CVD mortality, and all-cause mortality 4, 2, 3. Real-world evidence from a target trial emulation study of 118,271 patients demonstrated that intensive BP management (<130/80 mmHg) resulted in lower risk of hypertension-related complications and all-cause mortality without significant increased risk of serious adverse events 5.
Important Caveats
"As Low As Reasonably Achievable" (ALARA) Principle
When the target of 120-129/70-79 mmHg cannot be achieved due to tolerability issues, target BP as low as reasonably achievable 4, 1. This is a Class I recommendation acknowledging that some patients cannot tolerate intensive therapy.
Monitoring for Adverse Effects
While adverse effects (hypotension, syncope, electrolyte abnormalities, acute kidney injury) are more common with intensive targets, they remain infrequent with numbers needed to harm ranging from 508 to 3,222 2, 3. Careful monitoring is essential, particularly in older adults and those on multiple medications.
Divergence from 2023 ESH Guidelines
Notably, the 2023 ESH guidelines specifically recommend against targeting BP below 120/70 mmHg (Class III, harm) based on J-curve concerns 4. However, the 2024 ESC and 2025 AHA/ACC guidelines reject this position based on more recent trial evidence showing safety and efficacy of lower targets 4, 2, 3.
Practical Implementation
- Confirm target achievement with average of ≥2 readings at ≥2 visits, not individual measurements 2, 3
- Reassess monthly after initiation or medication changes until target is reached 6
- Follow-up every 3-5 months once BP is controlled 6
- Use out-of-office BP monitoring (home or ambulatory) to confirm control and detect white coat or masked hypertension 7